1. Two bond sales priced on the same day
Medical device maker Boston Scientific Corporation said on November 19, 2026, that it had priced two bond sales, $3 billion of dollar-denominated senior notes and €4.25 billion of euro-denominated notes, to help pay the cash portion of the Boston Scientific Penumbra acquisition. Both offerings are expected to close on December 1, 2026, subject to customary closing conditions.
Ten separate series of debt make up the package, four in dollars and six in euros, with maturities that begin in 2028 and stretch as far as 2046. The dollar notes are being issued by Boston Scientific itself. The euro notes are being issued by American Medical Systems Europe B.V., which the company describes as an indirect wholly owned finance subsidiary, and they carry a full and unconditional guarantee from the parent.
Pricing is the point at which a borrower and its banks settle the size, interest rate and maturity of each piece of a bond sale. It is not the same as receiving the money. The cash changes hands at closing, which in this case is scheduled for the first day of December. Between the two dates the terms are fixed, and investors who were allocated notes are committed to buying them as long as the usual conditions are met.
2. How is the Boston Scientific Penumbra acquisition being funded?
The purchase of Penumbra, Inc. will be paid for with a mix of sources: the money raised from the two note offerings, short-term borrowings, borrowings under the company's credit agreement and cash already on hand. Boston Scientific said the proceeds of the notes are intended to cover the cash consideration owed in the acquisition together with related fees and expenses.
Anything left over has a stated destination as well. The company said proceeds not needed for the acquisition would be put toward general corporate purposes. In its announcement that category covers short-term investments, paying down short-term debt, working capital and possible future acquisitions.
Spreading the bill across several funding sources is a common approach for a large cash purchase. Bonds with fixed maturities provide money that cannot be called back early by lenders, while short-term borrowings and credit lines can be drawn and repaid more flexibly as the buyer's cash position changes. Cash on hand, the simplest source of all, reduces how much has to be borrowed in the first place. The announcement does not break down how much each of the other sources will contribute.
3. Four dollar tranches with coupons from 5.375% to 5.875%
On the dollar side, the $3 billion is divided into four series. The largest is $1 billion of 5.375% senior notes due 2029. It is followed by $750 million of 5.500% senior notes due 2031, another $750 million of 5.750% senior notes due 2033, and $500 million of 5.875% senior notes due 2036.
The pattern is a familiar one in corporate debt: the longer the money is borrowed, the higher the annual interest rate attached to it. The shortest dollar series pays 5.375% and comes due in roughly three years, while the longest pays half a percentage point more and runs for about a decade. Investors generally ask for extra compensation to lend over longer periods because more can change, both at the company and in the wider interest rate environment, before they are repaid.
Senior notes rank ahead of subordinated debt and equity in a company's capital structure, which is why they are the standard instrument for acquisition financing of this kind. The coupon is the fixed rate of interest paid on the face value of each note until it matures, at which point the principal is returned to holders.
Three banks are acting as joint book-running managers for the dollar offering: BofA Securities, Citigroup Global Markets and J.P. Morgan Securities. Bookrunners organize the sale, gather orders from investors and help set the final terms.
4. Six euro series reaching out to 2046
Europe accounts for the larger share of the financing. The €4.25 billion euro offering consists of six series, beginning with €500 million of floating rate notes due 2028 and €500 million of 3.875% notes that mature in the same year.
The remaining four series extend much further into the future. They are €750 million of 4.125% notes due 2030, €750 million of 4.500% notes due 2034, €1 billion of 4.750% notes due 2038 and €750 million of 5.125% notes due 2046. The final series will not be repaid for about twenty years.
Floating rate notes differ from the rest of the package in one important respect. Their interest payments are not fixed at issuance but reset periodically in line with a market reference rate, so the cost to the borrower rises and falls with short-term interest rates. The other nine series across both currencies pay a fixed coupon for their entire life.
Issuing through American Medical Systems Europe B.V. rather than the parent is a structural choice. A finance subsidiary exists to raise money on behalf of a corporate group, and the guarantee from Boston Scientific means investors in the euro notes ultimately rely on the credit of the parent company. The guarantee is described as full and unconditional.
Taken together, the ten series spread repayment across nearly two decades, from 2028 to 2046. A staggered schedule of this kind avoids concentrating a very large repayment in a single year.
Raising money in two currencies also widens the pool of buyers. Dollar notes are placed mainly with investors who manage dollar portfolios, while euro notes reach funds, insurers and banks that prefer to hold euro assets. A borrower that taps both markets at once is not dependent on demand from a single group of lenders, and the lower coupons on the fixed-rate euro series, which range from 3.875% to 5.125%, compared with 5.375% to 5.875% on the dollar series, reflect the different interest rate conditions in the two currencies. Barclays Bank, Citigroup Global Markets Europe and J.P. Morgan SE are the bookrunners on the euro sale.
5. What happens to the notes if the Penumbra deal is not completed?
Nearly all of the new debt would have to be bought back at a small premium. Every series in both offerings, with the single exception of the floating rate notes, is subject to what is known as a special mandatory redemption. If the Penumbra acquisition is not completed by a specified end date, or if the issuer notifies the trustee that it will not pursue the acquisition, the affected notes must be redeemed at 101% of their principal amount, plus accrued and unpaid interest up to, but not including, the redemption date.
This kind of clause is a standard protection in bonds sold to fund a takeover before the takeover has closed. Investors are lending on the understanding that the money will finance a particular transaction. If that transaction disappears, the clause hands their money back with one extra percentage point on top, rather than leaving them holding long-dated debt issued for a purpose that no longer exists.
The announcement does not state the end date that would trigger the redemption.
Two further points define how the offerings relate to the deal and to each other. Neither offering is conditioned on completion of the Penumbra acquisition, meaning the notes can be issued on December 1 whether or not the purchase has closed by then. And neither offering is contingent on the other, so the dollar sale and the euro sale can each proceed independently.
6. What the financing means for the company and its shareholders
For holders of Boston Scientific shares, the bond sale settles one question and leaves another open. Long-dated, committed funding for the cash payment is now arranged on fixed terms, which removes a degree of uncertainty about how the purchase will be paid for. The debt itself, however, is a lasting commitment. Interest on the fixed-rate series will be owed every year until each one matures, and the final euro series remains outstanding until 2046.
The redemption clause also shows where the remaining uncertainty sits. Because most of the notes are tied to the acquisition actually being completed, the outcome of the deal, rather than the availability of money to pay for it, is the larger unresolved matter.
The offerings are being made under a registration statement filed with the Securities and Exchange Commission, using a prospectus and separate preliminary prospectus supplements for each sale. The company noted that its announcement is not an offer to sell the securities or a solicitation of offers to buy them.
7. The business behind the borrowing
Boston Scientific is headquartered in Marlborough, Massachusetts, and its shares trade on the New York Stock Exchange under the ticker BSX. The company describes itself as a global medical technology leader with a history of more than 45 years.
Its devices and therapies are used by physicians to diagnose and treat a broad range of conditions. The company lists cardiovascular, respiratory, digestive, oncological, neurological and urological diseases among the areas its portfolio addresses.
As is customary, the announcement was accompanied by cautionary language about factors that could affect the company's results. The risks it lists include movements in foreign exchange rates, tariff and trade policy, supply chain issues and litigation. It also refers to a cybersecurity incident that the company first reported on August 26, 2026, which continues to appear among its disclosed risk factors.
8. What comes next
The first date to watch is December 1, 2026, when both offerings are expected to close and the proceeds become available to the company, provided customary closing conditions are satisfied.
The second milestone is completion of the Penumbra acquisition itself. If the purchase closes before the special mandatory redemption end date, the notes simply remain outstanding and run to their scheduled maturities between 2028 and 2046. If it does not, or if the issuer tells the trustee it is abandoning the transaction, nine of the ten series would be redeemed at 101% of principal plus accrued interest, and only the €500 million of floating rate notes would be left in place.
